In the subgroup analysis which included 845 patients with paired tumor samples available from the pre‐neoadjuvant therapy core biopsy and surgical tumor specimen with HER2 status of the residual disease known, 8.3% of tumors were HER2‐negative after neoadjuvant treatment. This evidence concerns the gene ERBB2 and neoplasm.